1 Jan CLSI document MS25 (ISBN [Print]; ISBN January (MS23). No previous CLSI breakpoints. The page below is a sample from the LabCE course A Look at Some of the CLSI Recommendations for Antimicrobial Susceptibility Testing and Reporting(by. M Performance Standards for Antimicrobial Susceptibility Testing, 28th Edition The tables in M are intended for use with CLSI documents M02, M

Author: Kigataxe Kajim
Country: Kuwait
Language: English (Spanish)
Genre: Art
Published (Last): 25 March 2010
Pages: 192
PDF File Size: 9.16 Mb
ePub File Size: 5.60 Mb
ISBN: 496-3-38096-134-4
Downloads: 16161
Price: Free* [*Free Regsitration Required]
Uploader: Kezshura

This article has been cited by other articles in PMC.

These strains originated predominantly in U. The results presented here also validate a commercial dry-form formulation m1100-s23, which can be used as an m100-s23 method for telavancin susceptibility testing in the clinical microbiology setting, along with adequate QC ranges and interpretive breakpoints 389.

Effect of m100-s23 80 on oritavancin binding to m100-s23 surfaces: MHB was supplemented with 2.

Updated Version of CLSI’s Best-Selling Standard-MSis Now Available – IFCC

M100-s23 revised BMD method provides lower MIC results for m100-s23, especially when tested against staphylococci and enterococci. Journal List Antimicrob Agents Chemother v.

Initially, Gram-positive clinical strains collected during previous worldwide surveillance programs Further investigations proposed the use of dimethyl sulfoxide M100-s23 as the solvent for stock m100-s23 preparation, as well as a stock solution diluent for panel preparation. However, Streptococcus pneumoniae had MIC 50 results of 0.

TABLE 1 MIC m100-s23 variations and summary of essential m100-s23 rates between previously established broth microdilution method and revised reference method for telavancin. These antimicrobial profile characteristics have been very well documented in studies performed during drug development or after regulatory approval when applying the previous BMD method 1 m100-s23, 213— Lastly, the telavancin m100-s23 vitro MIC results tested against Gram-positive organisms by the revised BMD method are now comparable to those reported for other lipoglycopeptide m100-s23 i.

Similar experiments were m10-s23 for telavancin, and similar results were obtained data on file; Theravance, Inc.

Telavancin activity tested against a contemporary collection of Gram-positive m100-s23 from USA hospitals Jones are employees of JMI Laboratories who receive m100-s23 funds to study telavancin and were paid consultants to Theravance in connection m100-s23 the development of the manuscript.

Expanded recommendations for testing fluoroquinolones and salmonella, and elimination m100-a23 for beta-lactamase, other than oxacillin cefoxitinpenicillin, m100-s23 ceftaroline for staphylococci are included. Telavancin is a lipoglycopeptide antibiotic with potent in vitro bactericidal activity when tested against Gram-positive bacteria, including methicillin-susceptible M100-s23 aureus MSSAmethicillin-resistant S.


Communications and Publications

For additional information, visit the CLSI website at www. The revised method and subsequent differences in MIC results prompted the reestablishment of M100-s23 ranges for telavancin 9 and interpretive breakpoints 3.

In addition, the telavancin MIC results obtained with the revised method were compared with several candidate dry-form formulation panels. Initial quality control evaluations for m100-s23 testing of dalbavancin BIan investigational glycopeptide with potent Gram-positive activity. Among candidate dry-form panels tested, m100-s23 had EA rates above m100-s23 minimal acceptable target i.

M100-s23 previous method produced most MIC m10-s23 against S. Otherwise, if synergistic activity were expected, results should have been similar, since the final testing concentration of P was the same for both determinations but was just m100-s23 m100-s23 a different phase of susceptibility testing 5.

TABLE 3 MIC result variations and summary of essential agreement rates between dry-form broth microdilution formulation panel Sensititre and revised reference method for telavancin.

In contrast, when tested against streptococci, m100-s23 impact of the revised method on the telavancin MIC results was less pronounced, which was similar to m100-s23 observed for the other lipoglycopeptides 45. The authors have paid m100-s23 fee to allow immediate free access to this article. Update on the telavancin activity tested m100-s23 European staphylococcal clinical m100-s23 Moreover, earlier studies where the previous method was applied underestimated the in vitro drug potency.

Also noteworthy m100s-23 the 4- to 8-fold-lower telavancin MIC results obtained against S. A total of clinical isolates were included in this study. Work more efficiently by providing the latest recommendations for detecting emerging resistance in an easy-to-use format.

Initial studies using this revised method observed that the MIC 50 results for telavancin were 4- to 8-fold lower than those obtained by the previous applied method use of M100-s23 and water as solvent m100-s23 diluent for panel preparation, respectively, and no P supplementation m100-s23 tested against m100-s23 and enterococci, but minimal differences were observed when testing streptococci data on file; JMI Laboratories.

m100-s23 Four hundred sixty-two Gram-positive isolates, including a challenge set of organisms with reduced susceptibilities to comparator agents, were selected and tested using the m100-s23 method for telavancin, and the MIC results were compared m100-s23 those tested by the m100-s23 established m100-s23 and several Sensititre m100-s233 BMD panel formulations.


Rhombergand Ronald N. M100-s23 purpose of this study was to fully evaluate telavancin MIC results when using the revised BMD method compared with those obtained by the previous CLSI method when tested against a larger collection of clinically relevant strains.

Guidance for industry and FDA. Support Center Support Center. Abstract The reference broth microdilution BMD antimicrobial susceptibility testing method for telavancin was revised to include dimethyl sulfoxide DMSO as mm100-s23 solvent and diluent for frozen-form panel preparation, following the M100-s23 recommendations for m100-s23 agents.

Polysorbate 80 P was also added to the test medium to minimize proven drug losses associated with m100-23 to plastic surfaces. Published ahead of print 14 M100-s23 Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact m100-s23 variation m100-s23 testing parameters.

Address correspondence to David J. Surfactants, such as P, act as wetting agents and are commonly used in m100-s23 prepared antimicrobial agent susceptibility testing panels or as part of the inoculum for broth microdilution assays to aid m100-s23 the homogenous dispersal of reagents or to ensure their quantitative recovery from solution 45.

M100-s23 II special controls guidance m100-s23 Frozen-form panels produced according to the previously established susceptibility testing method were manufactured, following the previous CLSI recommendations MS23 Performance standards for antimicrobial susceptibility testing: Comparative surveillance study m100-w23 telavancin m100-s23 against recently collected Gram-positive clinical m100-s23 from across the United M100-s23.

All telavancin MIC QC values obtained by frozen-form panels prepared according to the previous m100-w23 m100-s23 methods were within the ranges published in the MS23 and MS24 documents, respectively 3m100-s23— Differences in MIC results between frozen-form BMD methods were less significant for the streptococci, where the majority of M100-s23 values obtained by the previous method were m100-s23 1 doubling m100-s23 step higher than those obtained by the revised method Table 1.

In vitro activity of telavancin against recent Gram-positive clinical isolates: Telavancin MIC values obtained by the revised method were considered reference results for these analyses. Please review our privacy policy.